Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer
1998

Dose Escalation Using CHARTWEL in Non-Small-Cell Lung Cancer

Sample size: 64 publication Evidence: moderate

Author Information

Author(s): MI Saunders, A Rojas, BE Lyn, K Pigott, M Powell, K Goodchild, PJ Hoskin, H Phillips, N Verma

Primary Institution: Marie Curie Research Wing, Mount Vernon Hospital

Hypothesis

Can a modified CHART schedule improve survival and reduce morbidity in non-small-cell lung cancer?

Conclusion

Increasing the radiation dose in the CHARTWEL schedule led to higher acute oesophageal morbidity and mild late lung dysfunction, but did not require more intensive medical management.

Supporting Evidence

  • Patients treated with CHARTWEL 60 Gy experienced more severe dysphagia than those treated with 54 Gy.
  • 60% of patients died due to failure to control locoregional disease.
  • Acute dysphagia and analgesia were more severe and lasted longer in patients treated with CHARTWEL 60 Gy.
  • At 12 weeks, oesophagitis was similar between both treatment groups.
  • Over 80% of patients treated with CHARTWEL 60 Gy showed some degree of lung impairment after two years.

Takeaway

Doctors tested a new way to give radiation to lung cancer patients and found that while it caused more side effects, it didn't make patients worse off overall.

Methodology

Patients were treated with either 54 Gy in 16 days or 60 Gy in 18 days, and their symptoms were monitored for acute and late morbidity.

Potential Biases

Potential selection bias in patient eligibility for the study.

Limitations

The study had a small sample size and was limited to specific patient demographics.

Participant Demographics

64 patients, 49 men and 15 women, aged 45-80 years (median 66 years).

Statistical Information

P-Value

0.004

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication